» Articles » PMID: 19185485

PI 3-kinase and Cancer: Changing Accents

Overview
Publisher Elsevier
Specialties Biology
Genetics
Date 2009 Feb 3
PMID 19185485
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Research on PI 3-kinase (PI3K) is undergoing significant shifts in emphasis. Questions that have been dormant for some time are coming to the forefront, such as the relationship of PTEN to PI3K and the role of AKT in PI3K-driven oncogenesis. Two non-alpha isoforms of Class I PI3K are now established as important determinants in cancer: p110beta and p110delta. The oncogenic activities of p110beta include a non-catalytic function, a finding that will have immediate consequences for drug development.

Citing Articles

Rs12039395 Variant Influences the Expression of hsa-miR-181a-5p and PTEN Toward Colorectal Cancer Risk.

El-Korany W, Zahran W, El-Din M, Al-Shenawy H, Soliman A Dig Dis Sci. 2024; 69(9):3318-3332.

PMID: 38940971 DOI: 10.1007/s10620-024-08517-3.


MiRNAs in Radiotherapy Resistance of Nasopharyngeal Carcinoma.

Tian Y, Tang L, Yi P, Pan Q, Han Y, Shi Y J Cancer. 2020; 11(13):3976-3985.

PMID: 32328201 PMC: 7171507. DOI: 10.7150/jca.42734.


For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors.

Buchanan C, Lee K, Shepherd P Biomolecules. 2019; 9(9).

PMID: 31443495 PMC: 6770514. DOI: 10.3390/biom9090402.


TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling.

Chen W, Luo K, Ke Z, Kuai B, He S, Jiang W J Cancer. 2017; 8(10):1892-1899.

PMID: 28819387 PMC: 5556653. DOI: 10.7150/jca.17638.


Scaffolding Function of PI3Kgamma Emerges from Enzyme's Shadow.

Mohan M, Naga Prasad S J Mol Biol. 2017; 429(6):763-772.

PMID: 28179187 PMC: 5390685. DOI: 10.1016/j.jmb.2017.01.023.


References
1.
Kang S, Denley A, Vanhaesebroeck B, Vogt P . Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006; 103(5):1289-94. PMC: 1360601. DOI: 10.1073/pnas.0510772103. View

2.
Denley A, Kang S, Karst U, Vogt P . Oncogenic signaling of class I PI3K isoforms. Oncogene. 2007; 27(18):2561-74. DOI: 10.1038/sj.onc.1210918. View

3.
Yuan T, Cantley L . PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27(41):5497-510. PMC: 3398461. DOI: 10.1038/onc.2008.245. View

4.
Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick J, Prie N, Verdier F . Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005; 106(3):1063-6. DOI: 10.1182/blood-2004-08-3225. View

5.
Keniry M, Parsons R . The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008; 27(41):5477-85. DOI: 10.1038/onc.2008.248. View